[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Norwegian University of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":613},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,49,78,112,142,172,198,212,242,271,289,319,341,367,397,423,442,462,487,514,538,553,568,583,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054123","smartwork---a-decision-support-system-to-promote-return-to-work-among-people-sick-listed-with-musculoskeletal-disorders-100054123",false,"NCT07034040","SmaRTWork - a Decision Support System to Promote Return to Work Among People Sick-listed With Musculoskeletal Disorders","SmaRTWork","Inclusion Criteria:\n\n* Individuals 20-59 years old (working age)\n* Living in Norway\n* Own a smart phone with internet access\n* Sick-listed due to a musculoskeletal disorder for up to 12 weeks\n* The main diagnosis for sick leave is back pain, neck pain or widespread pain. For example one of the following (ICPC-2 diagnoses codes): Neck symptom\u002Fcomplaint (L01), Back symptom\u002Fcomplaint (L02), Low back symptom\u002Fcomplaint (L03), Muscle pain (L18), Back syndrome without radiating pain (L84)\n\nExclusion Criteria:\n\n* Pregnant\n* No employer (unemployed or self-employed)\n* Poor Norwegian comprehension\n* Sick listed for more than 3 months the previous 12 months\n* Have a planned date for RTW during the next week\n* previous participation in the trial or concurrent participation in another study that could interfere with the current trial\n* Unable to take part in exercise\u002Fphysical activity (e.g., use of walking aids, unable to get up and down on the floor independently)\n* Leg pain worse than back pain\n* Red flags that could indicate serious underlying pathology:\n\n  * Changes in bladder or bowel function\n  * General feeling of being unwell (malaise), fever and\u002For unexplained weight loss\n  * Reduced muscle (motor) function, sensory loss, walking problems or balance problems\n  * Neck or back pain that started after the age of 55 or feel different from previous pain episodes\n  * Pain that does not improve with rest or light activity or pain that is much worse during the night\n  * Previous or ongoing cancer\n  * Use of steroids\u002Fimmune suppressing medications or drug use\n  * Pain that is trauma (injury) related\n* Serious ongoing somatic (e.g., unstable heart disease) or mental disorder (e.g., psychosis, ongoing manic episode, suicidal ideation)\n* Pain has not been assessed by a clinician","ALL","20 Years","59 Years",{"count":21,"type":22},298,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to evaluate the effect of an intervention, SmaRTWork, on return to work compared to usual care for individuals who are sick-listed due to musculoskeletal disorders. Potential participants are individuals of working age (20-59 years) sick-listed due to a musculoskeletal disorder (neck pain, low back pain, or widespread pain) for up to 12 weeks living in Norway. The primary outcome will be time to sustainable return to work. We will also evaluate the effect on other work outcomes and health outcomes. We will also interview participants and stakeholders about their experience with the intervention.",[28,29],"Sick Leave","Musculoskeletal",[31,32,33,34,35],"Sick leave","musculoskeletal disorder","sickness absence","return to work","mHealth","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":22},"2026-08",{"date":44,"type":22},"2028-12",{"name":46,"class":47},"Norwegian University of Science and Technology","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":77},"100409483","the-eminence-study---petmr-imaging-of-head-neck-cancer-100409483","NCT04612075","The EMINENCE Study - PET\u002FMR Imaging of Head Neck Cancer","EMINENCE","Inclusion Criteria:\n\n* willing and able to give full written consent according to the protocol approved by the Regional Ethics Committee\n* histologically confirmed squamous cell carcinoma in the head neck region (pharynx, larynx, oral cavity or sinonasal area)\n* locally advanced disease without sign of dissemination (T3\u002FT4 and\u002For N1-3, M0) on diagnostic imaging\n* scheduled for definitive radiotherapy with curative intent with or without concomitant chemotherapy\n* adequate renal function: Creatinine clearance ≥ 60 ml\u002Fminute\n* lymph node metastasis from cancer of unknown primary of the upper neck (i.e. level II-III) were PET\u002FCT is negative outside the head-neck region can be considered for inclusion at the discretion of the study investigators.\n\nExclusion Criteria:\n\n* general contraindications for MRI (pacemaker, aneurysm clips, any form of metal in the body, severe claustrophobia)\n* serious comorbidity (including previous or othe cancer) that in the opinion of the investigator would compromise the patient's ability to complete the study of interfere with the evaluation of the study objectives (e.g. poorly controlled diabetes mellitus)\n* histologically confirmed SCC of same or other origin within the last five years\n* patient wants to withdraw for any reason during the study","18 Years",{"count":58,"type":22},390,"OBSERVATIONAL","Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge. The improvements in radiotherapy are closely related to improvements in medical imaging. Functional imaging, where intratumoural characteristics such as tumour oxygenation, metabolism, and blood vessel function can be quantified, offers possibilities to personalize the radiotherapy. In this study we will establish the clinical workflow for PET- and MRI-based radiotherapy in HNC by acquiring images prior to and during radiotherapy to develop new concepts for image-based biologically adaptive radiotherapy, both based on photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. The investigators aim to contribute towards further developments of personalised high-precision radiotherapy for HNC patients resulting in improved outcome, reduced side-effects and better quality of life.",[62],"Head and Neck Neoplasms",[64,65,66,67,68],"Diagnostic Imaging","Functional Imaging","Nuclear magnetic Resonance Imaging","Positron-Emission Tomography","Radiotherapy","RECRUITING","2026-04-09",{"date":72,"type":40},"2026-04-14",{"date":74,"type":40},"2021-01-12",{"date":44,"type":22},{"name":46,"class":47},2,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100633069","socket-leg-interface-movements-in-transtibial-amputees-100633069","NCT07521891","Socket-leg Interface Movements in Transtibial Amputees","Socket-leg Interface Movements as a Measure of Dynamic Prosthetic Fit for Transtibial Amputees: An Exploratory Study","SLMinTTA","Inclusion Criteria:\n\n* Age ≥16 years\n* Unilateral transtibial amputation\n* Activity level K2-K4\n* Actively using a prosthesis for ≥12 months\n* Ability to understand and communicate in Norwegian (oral and written)\n* Digital file of current socket model available (required for test socket fabrication)\n\nExclusion Criteria:\n\n* Use of a thigh corset attached to the prosthesis\n* Requirement of a walker for ambulation\n* Open wounds, skin ulcers, or blisters on the residual limb\n* No liner\n* Missing digital socket model file\n* Medical advice to avoid physical activity similar to study tasks\n* Other medical conditions that may worsen with activity and have not been cleared by a healthcare professional","16 Years",{"count":88,"type":22},20,[25],"This exploratory interventional study investigates dynamic prosthetic fit in unilateral transtibial prosthesis users by objectively measuring socket-leg interface movements (SLMs) during functional activities. During one single study visit, participants complete standardized laboratory tasks using three different suspension systems (pin-lock, passive vacuum, and active vacuum) applied to a transparent replica of their current prosthetic socket. Motion capture, force measurements, and patient-reported outcomes are used to evaluate how suspension systems influence interface motion, rotation resistance, gait characteristics, and user comfort. The study aims to improve clinical understanding of prosthetic fit and support more informed prosthetic decision-making in routine care.",[92],"Transtibial Amputation - Unilateral",[94,95,96,97,98,99,100,101,102,103],"Transtibial amputation","Lower-limb prosthesis","Prosthetic socket fit","3D motion capture","Prosthesis comfort","Prosthetic rotation resistance","Pistoning","Prosthetic suspension systems","Prosthetic alignment","gait","2026-04-07",{"date":106,"type":40},"2026-04-13",{"date":108,"type":22},"2026-04-20",{"date":110,"type":22},"2029-12-27",{"name":46,"class":47},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100625435","prostate-risk-or-radiology-assessment-non-inferiority-design-upfront-mri-or-risk-calculator-in-men-with-suspected-prostate-cancer-100625435","NCT07422597","Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer","PRORAND - Prostate Risk or Radiology Assessment Non-inferiority Design, a Comparison of Upfront MRI vs Risk Calculator in Men With Suspected Prostate Cancer","PRORAND","Inclusion Criteria:\n\n* more than 10 years remaining life expectancy\n* Suspected localized prostate cancer\n* Suspicious DRE (cT2)\n* PSA 3-20 ng\u002Fml\n\nExclusion Criteria:\n\n* cT3 and\u002For cT4 (on DRE)\n* PSA \\>20 ng\u002Fml\n* Prior diagnosis of prostate cancer\n* Contraindications to MRI or to prostate biopsy\n* Medications known to affect serum PSA levels",true,"MALE","50 Years","75 Years",{"count":125,"type":22},1016,[25],"Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary. In others, the test is sufficiently elevated that men are referred for further investigations. Most men with an elevated PSA are offered an MRI examination of the prostate gland, and for some, a tissue sample of the prostate is also recommended if the suspicion of cancer is high enough. Although this comprehensive investigation reveals most clinically significant , or dangerous cases of cancer, many indolent, or \"harmless\" cancer cases are also detected, which would not have caused the man any harm during his lifetime (approximately 20% of all prostate cancer diagnoses diagnosed in current clinical practive). Cancer treatment is not recommended for such cases, but for many men, the diagnosis and subsequent follow-up can cause him and his family anxity and concern. In addition, prostate biopsies are unpleasant for the patient and the investigation process is resource-intensive for both the man and the health care service.\n\nRisk stratification uses machine learning methods to better identify the men who require further investigations with MRI and tissue samples. In this project, the investigators investigate whether the best risk stratification tools are non-inferior in detecting clinically significant prostate cancer compared to current practice, and whether they lead to fewer tissue samples, MRI scans, less health anxiety, and better cost-effectiveness.",[129],"Prostate Cancer",[131,132],"Suspected prostate cancer","Elevated PSA","2026-03-12",{"date":135,"type":40},"2026-03-16",{"date":137,"type":22},"2026-03-01",{"date":139,"type":22},"2029-12-31",{"name":46,"class":47},3,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100628543","optimization-and-testing-effectiveness-of-a-collaborative-intervention-for-school-attendance-problems-in-norwegian-municipalities-100628543","NCT07463001","Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Municipalities","Inclusion Criteria:\n\n1. Participants must be between the ages of 9 and 15 at the time of enrollment.\n2. Participants must have less than 80% attendance for the last 12 weeks of school at the time of screening.\n3. At least one parent has to talk and understand Norwegian.\n4. At least one parent has to be motivated to participate.\n5. The school must agree to participate in the intervention\n\nExclusion Criteria:\n\n1 The participant has a known diagnosis of autism-spectrum disorder, psychosis, and\u002For eating disorder.\n\n2\\. Participant needs acute psychiatric intervention.","9 Years","15 Years",{"count":151,"type":22},240,[25],"In this study we will investigate the effects of an intervention called Back2School, revised and adapted for Norwegian conditions on school attendance. A total of 240 participants will be recruited. All participants who have been enrolled will receive the intervention. Half of the participants will receive the intervention without delay (the experiment group), and the other half will receive it following a 13-week period (the control group). Following consent, screening for eligibility and randomization, the intervention will start with an assessment related to the individual participant and condition at the participants' school. Based on this a shared understanding and an intervention plan is developed. Over a 13-week period the youth, the family and the school, work together guided by the municipal team to increase attendance and solve problems related to this. Assessments will be carried out after the intervention and 6 months later.",[155],"School Attendance Problems",[157,158,159,160,161,162],"School attendance problems","Back2School","Norway","Randomized controlled trial","Cognitive Behavioral Therapy","Children and adolescents","2026-03-06",{"date":165,"type":40},"2026-03-10",{"date":167,"type":22},"2026-03-23",{"date":169,"type":22},"2029-03-01",{"name":46,"class":47},4,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":48},"100619817","atwork-the-relation-between-cognitive-functioning-common-mental-disorders-and-work-functioning-100619817","NCT07349550","AtWork: The Relation Between Cognitive Functioning, Common Mental Disorders and Work Functioning","AtWork","Inclusion Criteria:\n\n* diagnosis of depression and\u002For anxiety,\n* at risk of sick leave\n\nExclusion Criteria:\n\n* personality disorders cluster A or B,\n* ongoing substance abuse,\n* symptoms of psychosis,\n* acute suicidality,\n* serious somatic disorders","65 Years",{"count":181,"type":22},200,"Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.",[184,185],"Depression - Major Depressive Disorder","Anxiety",[187,188,189,185,31],"Metacognitive therapy","Work focus","Depression","2026-01-16",{"date":192,"type":40},"2026-01-21",{"date":194,"type":40},"2024-01-01",{"date":196,"type":22},"2032-08-01",{"name":46,"class":47},{"id":199,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":26,"conditions":203,"keywords":204,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":48},"100595560","Inclusion Criteria:\n\n* Individuals 20-59 years old (working age)\n* Living in Norway\n* Sick-listed due to a musculoskeletal disorder for up to 12 weeks\n* Musculoskeletal complaints are the main reason for sick leave.\n* The main diagnosis for sick leave is unspecific pain, for example one of the following (ICPC-2 diagnoses codes):\n* Neck symptom\u002Fcomplaint (L01)\n* Back symptom\u002Fcomplaint (L02)\n* Low back symptom\u002Fcomplaint (L03)\n* Muscle pain (L18)\n* Back syndrome without radiating pain (L84)\n\nExclusion Criteria:\n\n* Do not have a smartphone with internet access (i.e., to be able to download and access the SmaRTWork app).\n* Pregnant\n* No employer (unemployed or self-employed)\n* Poor Norwegian comprehension\n* Sick listed for more than 3 months the last year\n* Have a planned date for RTW during the next week\n* Have previously participated in the study or currently participating in other studies\n* Unable to take part in exercise\u002Fphysical activity (e.g., use of walking aids, unable to get up and down on the floor independently)\n* Leg pain worse than back pain\n* Red flags that could indicate serious underlying pathology:\n\n  * Changes in bladder or bowel function\n  * General feeling of being unwell (malaise), fever and\u002For unexplained weight loss\n  * Reduced muscle (motor) function, sensory loss, walking problems or balance problems\n  * Neck or back pain that started after the age of 55 or feel different from previous pain episodes\n  * Pain that does not improve with rest or light activity or pain that is much worse during the night\n  * Previous or ongoing cancer\n  * Use of steroids\u002Fimmune suppressing medications or drug use\n  * Pain that is trauma (injury) related\n* Serious ongoing somatic (e.g., unstable heart disease) or mental disorder (e.g., psychosis, ongoing manic episode, suicidal ideation) that prevents participation\n* Pain has not been assessed by a physician",{"count":21,"type":22},[25],[28,29],[31,32,33,34,35],"2026-01-14",{"date":207,"type":40},"2026-01-15",{"date":209,"type":22},"2026-03",{"date":44,"type":22},{"name":46,"class":47},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":120,"sex":17,"minAge":218,"maxAge":149,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":77},"100618519","building-healthy-food-environment-in-schools-evaluating-co-created-interventions-in-low-resource-settings-betternutrition4adolescent-100618519","NCT07332676","Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent","Inclusion Criteria:\n\n* Adolescents studying in grade 7 to 9 (aged 11-15 years) Exclusion criteria:\n\nExclusion Criteria:\n\n* Adolescents with siblings enrolled in schools assigned to a different trial arm to avoid clustering, with underlying medical conditions and those who plan to change school within one year of enrollment (during follow up period) will be excluded.","11 Years",{"count":220,"type":22},2600,[25],"The goal of this clinical trial is to learn if a multicomponent nutrition program developed together with the students, parents, teachers and canteen operators will improve nutrition status of adolescents. It will also learn about the acceptability and feasibility of implementing the program in the school settings. The main questions it aims to answer are:\n\nWhat is the effect of co-created multicomponent intervention promoting healthy food behavior and environment in schools on the proportion of normal weight adolescents? What proportion of the target adolescents and teachers does the intervention reach? What proportion of the schools are willing to implement the intervention? What was the level of fidelity of implementation of all components of the intervention and the barriers and facilitators to implementation? What is the cost for maintenance, and facilitators and barriers of sustainment? School going adolescents studying in grades 7 to 9 from 26 schools in India and 26 schools in Nepal will be enrolled in the trial and their height, weight, dietary behavior, mental well-being and physical activity will be measured at baseline and at 12 months follow up. After the baseline assessment the school community (students, school environment, parents, teachers, canteen operators) will receive the intervention.",[224,225,226],"Overweight Adolescents","Underweight","Obese Adolescents",[228,229,230,231,232,233],"nutrition","multicomponent nutrition intervention","co-creation","adolescent","low resource settings","Poor nutrition","2025-12-30",{"date":236,"type":40},"2026-01-12",{"date":238,"type":22},"2026-10",{"date":240,"type":22},"2027-12",{"name":46,"class":47},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":122,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":48},"100595754","time-restricted-eating-and-high-intensity-interval-training-for-metabolic-health-in-adults-with-overweightobesity-100595754","NCT07036562","Time-restricted Eating and High-intensity Interval Training for Metabolic Health in Adults With Overweight\u002FObesity","Time-restricted Eating and High-intensity Interval Training for Long-term Improvement in Metabolic Health","TREHIIT-3","Inclusion Criteria:\n\n* Body mass index ≥ 27 kg\u002Fm²\n* Able to walk or ride a bike \\> 60 min\n\nExclusion Criteria:\n\n* On-going pregnancy\n* Lactation within 24 weeks of study commencement\n* High-intensity exercise ≥ 1\u002Fweek\n* Habitual eating window ≤12 hours\u002Fday\n* Taking hypertension, glucose-, or lipid-lowering drugs\n* Body mass variation ≥ 4 kg three months prior to study commencement\n* Known diabetes mellitus (type 1 or 2) or cardiovascular disease\n* Working night shifts",{"count":251,"type":22},100,[25],"This study will investigate the effects of 12 months periodised time-restricted eating combined with high-intensity interval training compared with a control group on fat mass in adults with overweight\u002Fobesity. Participants in the intervention group will complete the intervention remotely and will receive follow-up by telephone. Before randomisation, after 6 months and after 12 months, the investigators will measure the participants' body composition, physical fitness, fasting blood glucose and insulin, blood lipids, and blood pressure. Physical activity, diet, sleep quality, appetite, and adherence to the intervention will also be measured. Secondary sub-analyses of sex differences in the responses to the intervention will be performed.",[255],"Overweight and Obesity",[257,258,259,260,261,262],"time-restricted eating","high-intensity interval training","exercise","diet","metabolic health","lifestyle intervention","2025-12-05",{"date":265,"type":40},"2025-12-12",{"date":267,"type":40},"2025-09-11",{"date":269,"type":22},"2027-07",{"name":46,"class":47},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":48},"100072823","bipolar-research-and-innovation-network---brain-100072823","NCT00201526","Bipolar Research And Innovation Network - BRAIN","Inclusion Criteria:\n\n* All admitted patients giving written consent to participate in the study\n\nExclusion Criteria:\n\n* Patients without competence for consent.",{"count":278,"type":22},3000,"To describe the broad spectrum of Bipolar Disorder patients admitted to out-patient and in-patient psychiatric departments in Norway. Include all admitted Bipolar patients both with and without co-morbid disorders.",[281],"Bipolar Disorder",[281],{"date":265,"type":40},{"date":285,"type":40},"2003-01",{"date":287,"type":22},"2030-01",{"name":46,"class":47},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":179,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":48},"100457428","a-3-day-course-for-cfsme-100457428","NCT05236465","A 3-day Course for CFS\u002FME","A 3-day Course for Adults With Chronic Fatigue Syndrome\u002FMyalgic Encephalopathy (CFS\u002FME): a Randomized Controlled Trial","Inclusion Criteria:\n\n* CFS\u002FME diagnosis based on the Canada Consensus Criteria.\n* At least 50% out of school\u002Fwork.\n* Readiness to change (corresponding to the preparation phase in transtheoretical model)\n* Has given informed consent.\n\nExclusion Criteria:\n\n* Assessed by a General Practitioner (GP):\n* Underlying physical illness or mental disorder that may explain the symptoms.\n* Suicide risk\u002Fprevious suicide attempts.\n* Pregnancy.\n* Bedridden and in need of continuous care.\n* Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.",{"count":251,"type":22},[25],"Chronic fatigue syndrome\u002FMyalgic encephalomyelitis (CFS\u002FME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS\u002FME is a challenging health problem as well as a societal problem.\n\nIn recent years, a doubling of the number of patients with a CFS\u002FME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS\u002FME. Municipalities have expenses in form of care, rehabilitation and other measures.\n\nThere is a lack of effective treatment for CFS\u002FME. Evidence-based knowledge is highly needed.\n\nIf the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.",[300,301],"Chronic Fatigue Syndrome","Myalgic Encephalomyelitis",[303,304,305,306,307,308,309,310],"Health education","Chronic Fatigue Syndrome\u002FMyalgic Encephalopathy (CFS\u002FME)","RCT","3-day Course","Physical function","Fatigue","Cognitive techniques","Behavioral activation","2025-11-25",{"date":313,"type":40},"2025-11-26",{"date":315,"type":40},"2022-03-21",{"date":317,"type":22},"2028-12-01",{"name":46,"class":47},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":77},"100496063","augmented-endobronchial-ultrasound-ebus-tbna-with-artificial-intelligence-100496063","NCT05739331","Augmented Endobronchial Ultrasound (EBUS-TBNA) With Artificial Intelligence","Automatic Segmentation of Mediastinal Lymph Nodes and Blood Vessels in Endobronchial Ultrasound (EBUS) Images Using a Deep Neural Network","Inclusion Criteria:\n\n* Subjects referred to thoracic department in any of the participating hospitals with undiagnosed enlarged mediastinal and hilar lymph nodes.\n* Subjects have to be ≥ 18 years of age\n\nExclusion Criteria:\n\n* Pregnancy\n* Any patient that the Investigator feels is not appropriate for this study for any reason.",{"count":327,"type":22},50,"To evaluate the usefulness of Deep neural network (DNN) in the evaluation of mediastinal and hilar lymph nodes with Endobronchial ultrasound (EBUS). The study will explore the feasibility of DNN to identify lymph nodes and blood vessel examined with EBUS.",[330,331,332],"Artificial Intelligence","Endobronchial Ultrasound","Lung Cancer","2025-08-18",{"date":335,"type":40},"2025-08-22",{"date":337,"type":40},"2023-05-01",{"date":339,"type":22},"2027-12-01",{"name":46,"class":47},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":120,"sex":17,"minAge":349,"maxAge":4,"enrollmentInfo":350,"targetDuration":352,"studyType":59,"phases":4,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":48},"100602025","memory-deterioration-in-alzheimer-disease-100602025","NCT07118137","Memory Deterioration in Alzheimer Disease","Translational Neuroscience CAG for Alzheimer's Disease","MemAD","Inclusion Criteria:\n\n* Confirmed diagnosis based on current ICD criteria for AD or MCI .\n* \\>55years.\n* Norwegian native speaker\n* Lives at home and not in a health institution\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \\> 2).\n* Presence of brain tumors.\n* History of traumatic brain injury.\n* History of cranial surgery.\n* Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).\n* Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.\n\n  7T MRI contraindications:\n* Large tattoos close to the head region, permanent makeup or unremoveable piercings\n* Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)\n* Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)","55 Years",{"count":351,"type":22},30,"1 Year","Semantic AD",[355,356,357,358],"Alzheimer Disease","Neurodegenerative Diseases","Magnetic Resonance Imaging","Memory Impairment","2025-08-04",{"date":361,"type":40},"2025-08-12",{"date":363,"type":40},"2023-10-15",{"date":365,"type":22},"2027-12-31",{"name":46,"class":47},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":120,"sex":17,"minAge":179,"maxAge":4,"enrollmentInfo":375,"targetDuration":377,"studyType":59,"phases":4,"briefSummary":378,"conditions":379,"keywords":384,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":48},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",{"count":376,"type":22},60,"5 Years","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[380,381,382,383],"Mild Cognitive Impairment","Alzheimer Disease, Late Onset","Cognitive Impairment","Dementia",[385,386,387,388,356,383,389],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Cognitive impairment",{"date":391,"type":40},"2025-08-07",{"date":393,"type":40},"2024-07-01",{"date":395,"type":22},"2030-12-29",{"name":46,"class":47},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":122,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":141},"100404882","physical-therapy-vs-surgical-decompression-for-lumbar-spinal-stenosis-100404882","NCT04552145","Physical Therapy vs Surgical Decompression for Lumbar Spinal Stenosis","Physical Therapy Versus Surgical Decompression for Lumbar Spinal Stenosis: A Multicenter Randomized Controlled Trial","PTvsSD","Inclusion Criteria:\n\n* Patients describing intermittent neurogenic claudication when walking and symptoms revealed by flexion of the spine.\n* MRI shows lumbar spinal stenosis in one or two levels measured.\n* The duration of the symptoms is longer than six months\n* The patient is a candidate for surgical treatment\n* The patient is capable of physical exercise\n\nExclusion Criteria:\n\n* Vascular intermittent claudication\n* Lumbar spinal stenosis in more than two levels\n* Previous low back surgery\n* Symptomatic lumbar disc herniation\n* Degenerative scoliosis with Cobbs angle 30 degrees or more\n* Degenerative spondylolisthesis grade 2 or more\n* Spondylolysis with spondylolisthesis\n* Recent osteoporotic fractures in the spine (last 6 month)\n* Severe symptomatic arthrosis in hip or knee\n* Locally advanced or metastatic cancer\n* ASA \\>3\n* Polyneuropathy recognized by neurography\n* Insufficient Norwegian language skills","80 Years",{"count":407,"type":22},232,[25],"This is a randomized controlled multicenter trail comparing physical therapy to surgical decompression in patients with lumbar spinal stenosis. The 0-hypothesis is that there is no difference in the efficacy of structured physical therapy compared to surgical decompression.\n\nOur aim is to evaluate if physical therapy can serve as a nonsurgical alternative for patients with LSS, where the severity of symptoms indicates the need of surgical decompression.",[411],"Spinal Stenosis",[413,414],"Surgery","Physical Therapy Modalities","2025-06-17",{"date":417,"type":40},"2025-06-22",{"date":419,"type":40},"2020-09-01",{"date":421,"type":22},"2027-08-31",{"name":46,"class":47},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":441,"locationsCount":141},"100371071","diagnostic-assessment-of-amino-acid-petmri-in-the-evaluation-of-glioma-and-brain-metastases-100371071","NCT04111588","Diagnostic Assessment of Amino Acid PET\u002FMRI in the Evaluation of Glioma and Brain Metastases","Inclusion Criteria:\n\n* Inclusion criteria Glioma (LGG, HGG and recurrent HGG):\n\n  * Planned treatment for WHO grade II-IV diffuse glioma\n  * Adult patients (\\>18 years)\n  * Planned tissue sampling for histopathological diagnosis.\n  * KPS \\>60 (able to care for self)\n\nInclusion criteria Brain Metastasis:\n\n* Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases\n* Planned surgery: Suspicion of brain metastasis or known diagnosis\n* Stereotactic surgery: Known primary cancer\n* Adult patients (\\>18 years)\n* Estimated survival at least 3 months after inclusion\n\nExclusion Criteria:\n\n* Exclusion criteria (Glioma and Brain Metastasis):\n\n  * Pacemakers or defibrillators not compatible with 3T MRI\n  * No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits).\n  * Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist)\n  * Breastfeeding\n  * Weight \\> 120 kg",{"count":430,"type":22},160,"MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes and recurrences.\n\nAmino acid PET has demonstrated a great potential for defining true tumor volume, differentiate viable tumor tissue from postoperative changes or radiation necrosis, selection of biopsy site, non-invasive grading of gliomas and for treatment planning and therapy response assessment. By combining PET with MRI, the diagnostic accuracy can improve significantly for these patients. More research is however needed to compare the most promising amino acid PET tracers in patients with glioma, but also to assess the diagnostic value of amino acid PET in patients with different brain metastases, where the knowledge concerning the uptake characteristics is limited.\n\nThree of the most promising amino acid tracers (\\[11C\\]-methyl-methionine (11C-MET), \\[18F\\] fluoro-ethyl-tyrosin (18F-FET) and anti-1-amino-3-\\[18F\\]fluorocyclobutane-1-carboxylic acid (18F-FACBC)) will be evaluated in 3 substudies in this project; WP1 Aminoacid PET\u002FMRI in low and high grade glioma; WP2 Role of 11C-MET in high-grade glioma Gamma Knife® radiosurgery; and WP3 Amino acid PET in brain metastasis.\n\nThe main aim of the study is to improve diagnostic accuracy, histopathological tissue sampling, delineation of tumor extent and therapy response assessment in gliomas and brain metastases with amino acid PET\u002FMRI.",[433],"Brain Neoplasms",[435,357,67,436],"Diagnosis","PET-tracer",{"date":417,"type":40},{"date":439,"type":40},"2019-11-25",{"date":365,"type":22},{"name":46,"class":47},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":461},"100550539","exercise-training-study-of-patients-with-claudicatio-intermittens-100550539","NCT06448390","Exercise Training Study of Patients With Claudicatio Intermittens","Randomized Clinical Trial on the Effects of Home-based Five Plus Exercise Training","Inclusion Criteria:\n\n1. Pain in the calves after 300 m, or less measured on a treadmill\n2. Stable symptoms last 6 months or more\n3. The pain must be gone within 5 minutes after the patients stop walking\n4. Ankle-Brachial index at 0.7 or lower at rest\n5. Using statins and antiplatelet drugs since at least 3 months\n6. age\\> 18 years\n7. Signed consent\n\nExclusion Criteria:\n\n1. pain in the hips or elsewhere outside the calves while walking\n2. Remaining pain more than 5 minutes after stopped walking.\n3. Impossible to compress the arteries while measruing ABI or ABI lower than 0.4\n4. Use of statins and antiplatelet drugs less than 3 months\n5. symptoms less than 6 months\n6. Diabetes measured with HbA1c being over 48 mmol\u002Fmol (6%)\n7. Revascularisation the last 6 months\n8. Pain in the calves after longer than 300 m measured on a treadmill\n9. Reduced mobility in the ankles\n10. Reduced physical ability to perform a test on a treadmill.\n11. Age less than 18 years\n12. General conditions that impairs the ability to take part in a training study including Obesity, KOLS, heart disease, arthrosis, inflammatory joint diseases .\n13. No Signed consent",{"count":251,"type":22},[25],"The aim of the study is to evaluate whether walking capacity in patients with intermittent claudication is improved more by home-based 5+ exercise training than by current recommendations of daily walking.",[453],"Claudication, Intermittent","2025-06-05",{"date":456,"type":40},"2025-06-06",{"date":194,"type":40},{"date":459,"type":22},"2025-12-31",{"name":46,"class":47},14,{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":48},"100539937","trust-ace---anticancer-treatment-cardiotoxicity-identification-by-echocardiography-100539937","NCT06310330","TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","Technology Revising Ultrasound Solutions for Tomorrow - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","TRUST-ACE","Inclusion Criteria:\n\n* Breast cancer and referral for follow-up to identify potential CTRCD\n\nExclusion Criteria:\n\n* Not willing or able to consent",{"count":471,"type":22},250,[25],"TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).\n\nSecondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.",[475],"Breast Neoplasm Malignant Primary",[477,478,479,480],"echocardiography","breast cancer","artificial intelligence","cardiotoxicity",{"date":456,"type":40},{"date":483,"type":40},"2024-03-08",{"date":485,"type":22},"2026-12-31",{"name":46,"class":47},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":120,"sex":17,"minAge":56,"maxAge":494,"enrollmentInfo":495,"targetDuration":496,"studyType":59,"phases":4,"briefSummary":497,"conditions":498,"keywords":503,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":48},"100505681","predisposing-factors-for-post-stroke-epilepsy-100505681","NCT05864547","Predisposing Factors for Post-stroke Epilepsy","PRESTEP","Inclusion Criteria:\n\n* First time stroke patients with capacity to consent, admitted to the stroke unit at St. Olavs hospital.\n* Modified Rankin Scale (mRS) ≤ 2 before the stroke\n\nExclusion Criteria:\n\n* Previous stroke or brain surgery\n* Traumatic brain injuries\n* Neurodegenerative diseases\n* Brain tumors\n* Epilepsy before the stroke\n* Hydrocephalus\n* Aphasia\n* Serious psychiatric disorders\n* MRI incompatibility and claustrophobia","85 Years",{"count":351,"type":22},"6 Months","The goal of this observational study is to learn about epilepsy after a stroke (post-stroke epilepsy). The main questions it aims to answer are:\n\n* What make some patients develop epilepsy after a stroke?\n* Does sleep have an impact on the development of post-stroke epilepsy?\n\nParticipants will undergo:\n\n* Electroencephalography (EEG)\n* Magnetic resonance imaging (MRI)\n* Polysomnography (only patients)\n\nBlood tests will also be taken. The patient group will be compared to the healthy controls. Researchers will also look into medical records of stroke patients hospitalized at St. Olavs hospital and collect relevant information.",[499,500,501,502],"Post Stroke Epilepsy","Stroke","Epilepsy","Seizures",[504,387,505,388,506],"Cerebrovascular Disorders","Central Nervous System Diseases","Vascular Diseases",{"date":508,"type":40},"2025-06-10",{"date":510,"type":40},"2023-05-08",{"date":512,"type":22},"2030-12",{"name":46,"class":47},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":522,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":48},"100327083","bariatric-surgery-and-pharmacokinetics-of-paracetamol-100327083","NCT03538457","Bariatric Surgery and Pharmacokinetics of Paracetamol","Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol","Inclusion Criteria:\n\n* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway\n* Being a Norwegian citizen\n\nExclusion Criteria:\n\n* Having previously undergone resections in the GI-tract","70 Years",{"count":523,"type":22},12,"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.",[526],"Obesity, Morbid",[528,529,530,531,532],"Bariatric surgery","Gastrointestinal tract","Biological availability","Pharmacokinetics","Acetaminophen",{"date":456,"type":40},{"date":535,"type":40},"2016-11-02",{"date":238,"type":22},{"name":46,"class":47},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":544,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":552,"locationsCount":48},"100326846","bariatric-surgery-and-pharmacokinetics-of-valsartan-100326846","NCT03535376","Bariatric Surgery and Pharmacokinetics of Valsartan","Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan",{"count":523,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on valsartan are investigated.",[526],[528,529,530,531,548],"Valsartan",{"date":456,"type":40},{"date":535,"type":40},{"date":238,"type":22},{"name":46,"class":47},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":559,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":566,"leadSponsor":567,"locationsCount":48},"100326625","bariatric-surgery-and-pharmacokinetics-of-venlafaxine-100326625","NCT03532477","Bariatric Surgery and Pharmacokinetics of Venlafaxine","Bariatric Surgery and Pharmacokinetics of Venlafaxine: BAR-MEDS Venlafaxine",{"count":523,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on venlafaxine are investigated.",[526],[528,529,530,531,563],"Venlafaxine Hydrochloride",{"date":508,"type":40},{"date":535,"type":40},{"date":238,"type":22},{"name":46,"class":47},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":574,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":575,"conditions":576,"keywords":577,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":582,"locationsCount":48},"100322338","bariatric-surgery-and-pharmacokinetics-of-irbesartan-100322338","NCT03476603","Bariatric Surgery and Pharmacokinetics of Irbesartan","Bariatric Surgery and Pharmacokinetics Irbesartan: BAR-MEDS Irbesartan",{"count":523,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on irbesartan are investigated.",[526],[528,529,530,531,578],"Irbesartan",{"date":456,"type":40},{"date":535,"type":40},{"date":238,"type":22},{"name":46,"class":47},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":589,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":596,"leadSponsor":597,"locationsCount":48},"100322334","bariatric-surgery-and-pharmacokinetics-of-hydrochlorothiazide-100322334","NCT03476551","Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","Bariatric Surgery and Pharmacokinetics Hydrochlorothiazide: BAR-MEDS Hydrochlorothiazide",{"count":523,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on hydrochlorothiazide are investigated.",[526],[528,529,530,531,593],"Hydrochlorothiazide",{"date":456,"type":40},{"date":535,"type":40},{"date":238,"type":22},{"name":46,"class":47},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":521,"enrollmentInfo":604,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":611,"leadSponsor":612,"locationsCount":48},"100322333","bariatric-surgery-and-pharmacokinetics-of-gabapentin-100322333","NCT03476538","Bariatric Surgery and Pharmacokinetics of Gabapentin","Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin",{"count":523,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.",[526],[528,529,530,531,608],"Gabapentin",{"date":456,"type":40},{"date":535,"type":40},{"date":238,"type":22},{"name":46,"class":47},""]